Pancreatic cancer trials recruiting in Oklahoma

All Pancreatic cancer trials nationally

Cities in Oklahoma

Recruiting trials in Oklahoma

• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
  NCT05932862 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
  NCT06906562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of DM002 in Patients With Advanced Solid Tumors
  NCT06751329 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
  NCT07409272 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
  NCT04858334 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
  NCT04239573 · Phase: Not specified · Ages: 50 Years to 75 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
  NCT03257033 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
  NCT06026410 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Oklahoma: Tulsa
• Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
  NCT06937177 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
  NCT06128551 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
  NCT05053971 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
  NCT05040360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• ctDNA Assay in Patients With Resectable Pancreatic Cancer
  NCT05052671 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: All (male and female) · Oklahoma: Oklahoma City, Tulsa